Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
Date:2/23/2012

INCLINE VILLAGE, Nev., Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Total revenues in 2011 were $362 million, compared to $345 million in 2010, with royalty revenues increasing two percent over full year 2010. For the fourth quarter of 2011, total revenues were $72.8 million, compared to $76.1 million in the fourth quarter of 2010.

Royalty revenues for the fourth quarter of 2011 are based on third quarter product sales by PDL's licensees. The fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin®, which are marketed by Genentech and Roche, partially offset by increased royalties from third quarter 2011 sales of Lucentis® which is marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the fourth quarter and 2011 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2011 were $18.3 million, compared with $133.9 million in 2010. Included in operating expenses in 2010 is a $92.5 million legal settlement with MedImmune and $41.4 million in general and administrative expenses. For the fourth quarter of 2011, general and administrative expenses were $4.8 million compared with $12.1 million for the same period of 2010.

Net income in 2011 was $199.4 million, or $1.15 per diluted share as compared with net income of $91.9 million in 2010 or $0.54 per diluted share. Net income for the fourth quarter of 2011 was $38.9 million or $0.24 per diluted share as compared with a n
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a ... Drug Administration (FDA) for the use of Medtronic,s ... (including a newly developed catheter) for use with ... intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... - In Wisconsin, there is a growing belief that ... the loss of local ownership inevitably harms the state's economy. ... Corp . by Illinois-based CDW Corp . has a ... to those closest to the deal. , ,The win-win view ...
... expiring patents, generic drugs, and increasing costs of ... are increasingly turning to innovative biotechnology companies to ... business opportunities. , ,At a recent meeting of ... , pharmaceutical company representatives from Astellas Pharma, ...
... second consecutive year, the City of Madison received ... municipalities in the country. , ,In its 2006 Digital ... national research and advisory institute on information technology and best ... the top user of technology in its 125,000-249,999 population category. ...
Cached Biology Technology:Anatomy of a deal: CDW and Berbee 2Anatomy of a deal: CDW and Berbee 3Anatomy of a deal: CDW and Berbee 4Big pharma seeks Wisconsin biotech partnerships 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency ... to detect and prevent counterfeit microcircuits from entering ... agency started performing an in-house microcircuit anti-counterfeit initiative ... authenticity of purchased microcircuits while increasing their reliability ... measures will be conducted at DLA,s Electronics Product ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Nautiloids are the sole surviving family of externally-shelled ... million years ago. However, in the intervening years ... and developed complex central nervous systems; which makes ... that led to the development of the complex ...
... Micro gyro . . . Airplanes, submarines ... arrays of inexpensive high-performance micro-mechanical gyroscopes for navigation and ... being developed by a team consisting of Panos Datskos, ... Laboratory is radically different than today,s gyroscopes, which are ...
... highly developed emotional sensibilities are better at making product ... of Consumer Research. "Consumers who understand their emotional ... health decisions and product choices," explain the authors, Blair ... of Kentucky). "A person can know a lot about ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2008 3
...
... Peptide-Protein Conjugation, ... Bridges, Complex Peptides/Peptidomimetics, Special ... Phosphorylated/Biotinylated Structures, Peptide labeling AMC, ... -99%, fitting your needs, Chromogenic/Flurogenic ...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
...
Biology Products: